NASDAQ · Biotechnology

Roivant Sciences Ltd. (ROIV) Stock

$33.32 -1.74% NASDAQ: ROIV Healthcare

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs.

Valuation

MetricValue
Price$33.32
Market Cap$24.07B
P/E Ratio-24.64
P/B Ratio4.75
P/S Ratio1586.26
EPS (TTM)$-0.24
52-Week High$36.85
52-Week Low$10.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-19.14%
ROA-14.47%
ROCE-19.34%
Gross Margin-3458.62%
Operating Margin-3458.62%
Net Margin-60.80%
Debt/Equity0.05
Current Ratio33.56

Annual Financials (USD)

Metric20202021202220232024
Revenue$24.0M$55.0M$61.0M$33.0M$29.0M
Operating Profit$-1.1B$-1.4B$-1.2B$4.5B$-1.0B
Net Profit$-809.0M$-845.0M$-1.0B$4.3B$-172.0M
EPS$-1.18$-1.26$-1.42$5.23$-0.24
Op Margin-4500.5%-2444.8%-1918.0%13746.9%-3453.3%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$2.7B$2.6B$2.4B$7.2B$5.4B
Total Liabilities$528.0M$524.0M$782.0M$774.0M$250.0M
Cash$2.1B$2.1B$1.7B$6.5B$2.7B
Borrowings$245.0M$284.0M$481.0M$500.0M$100.0M

Latest News

Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents MT Newswires · Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders GlobeNewswire · Jul 16, 2026 ROIV: Lowering target price to $37.00 Argus Research · Jul 15, 2026 ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week Stocktwits · Jul 7, 2026 Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? Motley Fool · Jul 7, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-552.0M$-678.0M$-843.0M$-765.0M$-839.0M
Investing Cash Flow$-38.0M$286.0M$-57.0M$5.2B$-1.8B
Financing Cash Flow$1.0M$292.0M$-10.0M$18.0M$-1.3B
Net Cash Flow$-128.0M$-68.0M$-382.0M$4.9B$-3.8B
Free Cash Flow$-558.0M$-695.0M$-856.0M$-767.0M$-844.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-3.85%
Quick Ratio30.66
Interest Coverage—
Return 1Y204.53%
Return 3Y215.24%
Return 5Y253.13%

Ownership

Insiders Held23.39%
Institutions Held76.19%
Institutions Float Held99.44%
Institutional HolderSharesReport Date
FMR, LLC77,981,2532026-03-31
Morgan Stanley51,828,3252026-03-31
Blackrock Inc.44,254,2602026-03-31
QVT Financial LP25,161,2372026-03-31
UBS Group AG22,619,4722026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASNDAscendis Pharma A/S $243.45 -0.19% 25.59 $15.12B 0.00%
BBIOBridgeBio Pharma, Inc. $85.33 +1.56% -22.41 $16.71B 0.00%
EXASExact Sciences Corporation $104.91 — -95.37 $20.03B 0.00%
IONS $54.37 -2.84% -41.80 $8.99B 0.00%
JAZZJazz Pharmaceuticals plc $258.38 +0.94% 2071.27 $16.23B 0.00%

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Roivant Sciences Ltd. is led by CEO Matthew Gline, employs 721 people, headquartered in London, GB, publicly traded since 2020.

Roivant Sciences Ltd. (ROIV) stock trades at $33.32 with a market capitalization of $24.07B. The stock is valued at a price-to-earnings (P/E) ratio of -24.64, price-to-book of 4.75, price-to-sales of 1586.26. Over the past 52 weeks the stock has ranged between $10.71 and $36.85, and currently trades 9.6% below its 52-week high.

On profitability, Roivant Sciences Ltd. generates a return on equity (ROE) of -19.14%, return on capital employed of -19.34%, an operating margin of -3458.62%, a net profit margin of -60.80%.

In its most recent fiscal year, Roivant Sciences Ltd. reported annual revenue of $29.0M, net profit of $-172.0M, revenue has compounded at -15.7% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.05 — a conservative balance sheet with little leverage risk, a current ratio of 33.56, total assets of $5.4B, $2.7B in cash and equivalents.

ROIV has an average daily trading volume of 5,818,785 shares, a beta of 1.14.

Official website: roivant.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides